SSY GROUP Receives Medical Device Registration Certificates for Two Diagnostic Kits in Hebei

Stock News05-06

SSY GROUP (02005) announced that its two medical device products—the Full-range C-reactive Protein (hsCRP + conventional CRP) Detection Kit (Fluorescence Immunochromatography) and the Serum Amyloid A/C-reactive Protein (SAA/CRP) Detection Kit (Fluorescence Immunochromatography)—have been granted medical device registration certificates by the Hebei Provincial Medical Products Administration in China. The Full-range C-reactive Protein Detection Kit is designed for the in vitro quantitative detection of C-reactive protein levels in human whole blood, serum, and plasma samples, and is clinically used to assist in the diagnosis of nonspecific inflammation and cardiovascular diseases. The Serum Amyloid A/C-reactive Protein Detection Kit is intended for the in vitro quantitative detection of Serum Amyloid A (SAA) and C-reactive Protein (CRP) levels in human serum, plasma, or whole blood samples, and is clinically applied to support the diagnosis of nonspecific inflammation. The successive approvals of multiple detection kits open a new growth pathway for the Group in the medical device product segment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment